STAT+: With cash running short, Bluebird Bio and its gene therapies face uncertain future
Bluebird Bio, the troubled developer of gene therapies, has warned that cash is running short, creating “substantial doubt” about its ability to remain in business after this year.
The company ended 2021 with $397 million to fund operations, but said its projected cash burn for this year is expected to be “less than” $400 million.
